TECH Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.…
Industry Peers
BiotechnologyKey Statistics
About Bio-Techne (NASDAQ: TECH)
›
Bio-Techne (NASDAQ: TECH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3,000 employees.
The shares were at 72.70 USD on 19 November 2026, up 21.8% over 52 weeks. Its 52-week range is 43.20 USD to 72.88 USD, and it trades at the top of that range.
At a market capitalisation of 11.42B USD, it trades at 66.7 times trailing earnings and 31.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 99% for TECH. It pays a dividend yielding 0.44% (it pays out 29% of its earnings), against a median of 0.94% among the dividend payers in that peer group.
Bio-Techne reports return on equity of 8.6%, an operating margin of 21.7% and revenue up 4.6% year over year.
It holds more cash than debt, a net cash position of 65.57M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 10 analysts cover the stock, with an average rating of Hold; their mean price target of 70.50 USD is 3.0% below the current price. The next earnings report is expected on 9 February 2027.